BioSig Technologies Inc. raised $1.5 million through a securities purchase agreement with certain investors.

The Los Angeles-based medical device company sold 1,000 series E preferred shares and 500,000 warrants to buy common shares. Each warrant has an exercise price of $1.75, includes a "full ratchet" anti-dilution adjustment and is valid until Aug. 16, 2021.

Additionally, BioSig Technologies entered into a consent agreement with holders of its series D convertible preferred stock, under which it issued warrants to buy up to 100,000 common shares. Each warrant has an exercise price of $1.50, includes a "full ratchet" anti-dilution adjustment and is valid until Feb. 14, 2021.